Status:
COMPLETED
Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Lead Sponsor:
University of Arkansas
Conditions:
Alzheimer Disease
Neurodegenerative Diseases
Eligibility:
All Genders
19-89 years
Phase:
NA
Brief Summary
Degenerative dementias including Alzheimer's Disease (AD), Parkinson's Disease with Dementia (PDD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementias (FTLD), Corticobasal Degeneration (CBD) an...
Eligibility Criteria
Inclusion
- Diagnosed with idiopathic Parkinson's disease, progressive supranuclear palsy, Alzheimer's disease or Mild Cognitive Impairment based on consensus criteria, or suspicion of presbylarynx based on clinical evaluation.
- Require evaluation of voice dysfunction by an ENT doctor given symptoms of impaired voice volume or quality
- Age ≥ 18 years-old to ≤ 90-years old.
- Ability to understand and the willingness to sign a written informed consent.
Exclusion
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Active nose bleeds, or abnormal anatomy of the nose that prevent safe nasal swabs, or active oropharyngeal disease that prevents laryngoscopy or voice assessments.
Key Trial Info
Start Date :
November 14 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 21 2021
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT03299062
Start Date
November 14 2017
End Date
December 21 2021
Last Update
November 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205